I've recently been following the BBC's excellent "Human Planet" series. Last week's program was a fascinating insight into how the Inuit of the Arctic have adapted human existence, over centuries, to live in one of the harshest environments known to man. Why mention this on a blog about biotech funding?
Continue reading "Biotech Survival Lessons from the Inuit" »
This month we highlight a paper published earlier this year in Drug Discovery Today. The article, "Does R&D Pay?" looks at the effectiveness of different R&D strategies. This is achieved by looking at 10 year historical financial performance of different types of drug firms (big pharma, specialty/ generic, and biotech).
And it leads to some interesting conclusions about where investors might get the best return...
Part of our remit at ATPBio is to uncover value within the healthcare sector. More usually, this is in the form of working with clients to assist with strategy, asset work-up, due diligence and identifying key value drivers. Though, as we approach the festive season and thoughts turn
Does the current pain of financing just affect small underfunded companies, with weak pipelines? It seems not. Last month, Vertex announced it was selling its European milestone payments for its ph III program, Telaprevir for hepatitis C. Key points in the release, regarding the value of these
In these challenging times how can we get more out of less? Here are some interesting tips on improving productivity, and the value of daydreaming:
In his book, "The Seven Habbits of Highly Effective People", Steven Covery relays
Recent Comments